Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business board appointment

Avacta Appoints Mats Blom Audit Chair

Analysis based on 7 articles · First reported Sep 14, 2026 · Last updated Sep 15, 2026

Sentiment
5
Attention
1
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The appointment is a routine governance change for a small-cap AIM-listed biotech and is unlikely to move broader markets, though it modestly supports Avacta Group shares by strengthening board financial oversight. Investors will focus on the company's clinical catalysts, notably AVA6103 FOCUS-01 data expected in late 2026, rather than on the board reshuffle itself.

biotechnology pharmaceuticals

Avacta Group Therapeutics, a clinical-stage biopharmaceutical company listed on AIM under ticker AVCT, announced on September 14, 2026 the appointment of seasoned biotechnology finance executive Mats Blom to its Board of Directors as a non-executive director and Chair of the Audit Committee. As part of this board evolution, current Audit Committee Chair Paul Fry indicated his intention to step down from the Board effective September 30, 2026, allowing for an orderly transfer of his responsibilities to Blom. CEO Christina Coughlin welcomed Blom, citing his deep financial expertise and extensive experience in the biotechnology and life sciences sectors across the US and Europe as instrumental to advancing the company's pre|CISION tumor-activated oncology delivery platform and delivering on clinical and strategic milestones. Blom, aged 61, has held CFO roles at several life sciences companies including Zealand Pharma A/S from 2010 to 2019, where he oversaw its Nasdaq listing and earlier IPO on Nasdaq OMX Copenhagen, as well as at Active Biotech and Anoto Group. He currently chairs the Board of Egetis Therapeutics AB and serves on the Boards of GT Biopharma AB and privately held Pephexia Therapeutics ApS. He was previously a Board member at Nasdaq-listed Coya Therapeutics and held positions at NorthSea Therapeutics USA Inc, Modus Therapeutics and Swedish Orphan International. Earlier in his career he was a management consultant at Capgemini and Ernst & Young, and holds a BA from Lund University and an MBA from IESE Business School. Avacta Group shares traded up 1.99% at GBp 77 on the Aquis Stock Exchange following the announcement. The company anticipates releasing initial clinical data for AVA6103 from the FOCUS-01 trial in the late second half of 2026 and plans payload and clinical candidate selection for the AVA6207 program in the second half of 2026.

80 Avacta Group appointed Mats Blom
60 Paul Fry stepped down Avacta Group
stock
The company appoints Mats Blom to its board and Audit Committee chair, strengthening governance as it advances its pre|CISION oncology pipeline; shares rose 1.99% to GBp 77 on the news.
Importance 100.0 Sentiment 10.0
per
Appointed as non-executive director and Audit Committee Chair of Avacta Group, bringing extensive biotech CFO and board experience to the role.
Importance 95.0 Sentiment 5.0
per
Current Audit Committee Chair stepping down from the Avacta Group board effective September 30, 2026, after seven years of service, enabling an orderly handover to Blom.
Importance 60.0 Sentiment 0.0
per
Avacta Group CEO who welcomed Blom's appointment, highlighting his financial expertise as instrumental to advancing the pre|CISION platform and strategic milestones.
Importance 40.0 Sentiment 5.0
exch
Exchange where Avacta Group shares trade and where the RNS announcement was distributed; Avacta Group stock rose 1.99% to GBp 77.
Importance 15.0 Sentiment 0.0
stock
Former employer of Mats Blom, where he served as CFO from 2010 to 2019 and oversaw its Nasdaq listing and Copenhagen IPO; no direct impact from this event.
Importance 10.0 Sentiment 0.0
priv
Company whose board Mats Blom currently chairs; referenced as part of his current directorships.
Importance 8.0 Sentiment 0.0
stock
Company where Mats Blom currently serves as a board member; referenced as part of his current directorships.
Importance 8.0 Sentiment 0.0
exch
Exchange referenced in Mats Blom's career history regarding listings of Zealand Pharma and Coya Therapeutics.
Importance 5.0 Sentiment 0.0
priv
Former employer of Mats Blom in a CFO capacity; mentioned only as background on his career.
Importance 5.0 Sentiment 0.0
priv
Former employer of Mats Blom in a CFO capacity; mentioned only as background on his career.
Importance 5.0 Sentiment 0.0
priv
Privately held company where Mats Blom currently serves as a board member; mentioned as background.
Importance 5.0 Sentiment 0.0
stock
Nasdaq-listed company where Mats Blom was previously a board member; mentioned as background.
Importance 5.0 Sentiment 0.0
priv
Avacta Group's nominated adviser listed in the announcement contact details; no direct impact from the event.
Importance 5.0 Sentiment 0.0
priv
Avacta Group's broker listed in the announcement contact details; no direct impact from the event.
Importance 5.0 Sentiment 0.0
+ 8 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.